Newsletter | October 8, 2019

10.08.19 -- Optimizing Drug Safety And Efficacy Of Complex Next-Generation Biologics

 
Sponsor
  In Vivo Models And In Vitro Assays For Human RSV Infection - Pre-Clinical Antibody, Small Molecule And Vaccine Development
 

Despite over 50 years of research, there remains no licensed vaccine product and disease due to RSV infection remains an unmet medical need. In vitro & in vivo models for RSV vaccine development can provide a critical component in development of anti-RSV antibodies, small molecules and vaccines. Learn how customized and high quality pre-clinical animal models and ex vivo readouts can support your anti-RSV biologics development from concept all the way to IND. Learn more.

Industry Insights
"Validation" Or "Qualification": What’s The Difference?
Article | By Praveen Bezawada-Joseph, Thermo Fisher Scientific

What is the difference between qualification and validation? This question comes up frequently with both internal and external clients. 

Unlock Oral Delivery Potential For Macromolecules With A Parallel Screening Approach
Application Note | Catalent

Identifying the optimal formulation and dose form which shows an increase more than 20 times in the oral bioavailability of Salmon Calcitonin.

Optimizing Drug Safety And Efficacy Of Complex Next-Generation Biologics
White Paper | GE Healthcare Life Sciences

Learn what challenges exist when developing biologic drugs to be efficacious but safe and how novel analytical techniques, like surface plasmon resonance, can help circumvent these issues and optimize development.

Most Popular News
Life Science Leader Magazine
 

Have you heard of Life Science Leader?
Check it out today for access to candid interviews with top-tier executives on how they do business.